Blar i forfatter Det helsevitenskapelige fakultet "Lundgren, Steinar"

Viser treff 1-11 av 11

    • CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer 

      Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun; Østenstad, Bjørn; Lundgren, Steinar; Berge, Elisabet O.; Risberg, Terje; Mjaaland, Ingvil; Mæhle, Lovise; Engebretsen, Lars Fredrik; Lillehaug, Johan Richard; Lønning, Per Eystein (Journal article; Tidsskriftartikkel; Peer reviewed, 2008-08-26)
      Background Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene expression profiles have failed to identify mechanisms causing in vivo resistance to anthracyclines. While we previously found TP53 mutations in the L2/L3 domains to ...

    • Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo 

      Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan; Geisler, Stephanie; Staalesen, Vidar; Leirvaag, Beryl; Yndestad, Synnøve; de Faveri, Elise Norheim; Karlsen, Bård Ove; Wedge, David C.; Akslen, Lars A.; Lilleng, Peer Kåre; Løkkevik, Erik; Lundgren, Steinar; Østenstad, Bjørn; Risberg, Terje; Mjaaland, Ingvil; Aas, Turid; Lønning, Per Eystein (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-05-08)
      Chemoresistance is the main obstacle to cancer cure. Contrasting studies focusing on single gene mutations, we hypothesize chemoresistance to be due to inactivation of key pathways affecting cellular mechanisms such as apoptosis, senescence, or DNA repair. In support of this hypothesis, we have previously shown inactivation of either TP53 or its key activators CHK2 and ATM to predict resistance ...

    • Dietary changes in early-stage breast cancer patients from pre-surgery and over the 12 months post-surgery 

      Brunvoll, Sonja Hjellegjerde; Thune, Inger; Bertheussen, Gro Falkener; Fjeldheim, Frøydis Nyborg; Flote, Vidar Gordon; Frydenberg, Hanne; Lundgren, Steinar; Skjerven, Helle; Lømo, Jon; Fagerland, Morten; McTiernan, Anne; Schlichting, Ellen; Hjartåker, Anette (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-08-19)
      The time after a breast cancer diagnosis is a potential period for making positive dietary changes, but previous results are conflicting. The main aim of the present study was to study breast cancer patients’ dietary changes during the 12 months post-surgery and from 12 months pre-surgery to 12 months post-surgery with repeated administration of a 7-d pre-coded food diary and an FFQ, respectively. ...

    • Genome-Wide Profile of Pleural Mesothelioma versus Parietal and Visceral Pleura : The emerging Gene Portrait of the Mesothelioma Phenotype 

      Olsen, Karina Standahl; Røe, Oluf Dimitri; Anderssen, Endre; Helge, Eli; Pettersen, Caroline Hild; Sandeck, H; Haaverstad, Rune; Lundgren, Steinar; Larsson, Erik (Journal article; Tidsskriftartikkel; Peer reviewed, 2009)

    • Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer 

      Yndestad, Synnøve; Engebrethsen, Christina; Herencia-Ropero, A.; Nikolaienko, Oleksii; Vintermyr, Olav Karsten; Lillestøl, Reidun Kristine; Minsaas, Laura; Leirvaag, Beryl; Iversen, Gjertrud Titlestad; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Aase, Hildegunn Siv; Aas, Turid; Gudlaugsson, Einar; Llop-Guevara, Alba; Serra, Violeta; Janssen, Emiel; Lønning, Per Eystein; Knappskog, Stian; Eikesdal, Hans Petter (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-12-01)
      Purpose - Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to assess the potential for PARPi in a wider group of patients with breast cancer.<p> <p>Methods - HRD status was established using targeted gene panel sequencing (360 genes) and ...

    • Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer 

      Vaysse, Charlotte; Lømo, Jon; Garred, Øystein; Fjeldheim, Frøydis Nyborg; Lofterød, Trygve; Schlichting, Ellen; McTiernan, Anne; Frydenberg, Hanne; Husøy, Anders; Lundgren, Steinar; Fagerland, Morten W; Richardsen, Elin; Wist, Erik; Muller, Catherine; Thune, Inger (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-05-03)
      Growing evidence indicates that adiposity is associated with breast cancer risk and negatively affects breast cancer recurrence and survival, a paracrine role of mammary adipose tissue being very likely in this process. In contrast to other adipose depots, occurrence of a sub-inflammatory state of mammary adipose tissue defined by dying adipocytes surrounded by macrophages forming crown-like structures ...

    • Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer 

      Knappskog, Stian; Chrisanthar, Ranjan; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Leirvaag, Beryl; Miletic, Hrvoje; Lønning, Per Eystein (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-03-15)
      <i>Introduction</i>: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNA-damaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and Chk2 in response to genotoxic stress. Here, we sought to evaluate ATM's potential role in resistance to chemotherapy.<p> <p><i>Methods</i>: We sequenced <i>ATM</i> and ...

    • Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment 

      Madssen, Torfinn Støve; Thune, Inger; Flote, Vidar Gordon; Lundgren, Steinar; Bertheussen, Gro Falkener; Frydenberg, Hanne; Wist, Erik; Schlichting, Ellen; Schäfer, Hartmut; Fjøsne, Hans Erikssønn; Vettukattil, Muhammad Riyas; Lømo, Jon; Bathen, Tone Frost; Giskeødegård, Guro F. (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-07)
      <p><i>Background</i>: Breast cancer treatment has metabolic side effects, potentially affecting risk of cardiovascular disease (CVD) and recurrence. We aimed to compare alterations in serum metabolites and lipoproteins during treatment between recipients and non-recipients of chemotherapy, and describe metabolite profiles associated with treatment-related weight gain.</p> <p><i>Methods</i>: This ...

    • Nephronectin is Correlated with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs 

      Steigedal, Tonje S.; Toraskar, Jimita; Redvers, Richard P.; Valla, Marit; Magnussen, Synnøve; Bofin, Anna M.; Opdahl, Signe; Lundgren, Steinar; Eckhardt, Bedrich L.; Lamar, John M.; Doherty, Judy; Hynes, Richard O.; Anderson, Robin L.; Svineng, Gunbjørg (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-03-11)
      Most cancer patients with solid tumors who succumb to their illness die of metastatic disease. While early detection and improved treatment have led to reduced mortality, even for those with metastatic cancer, some patients still respond poorly to treatment. Understanding the mechanisms of metastasis is important to improve prognostication, to stratify patients for treatment, and to identify new ...

    • Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 

      Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-11-23)
      <p><i>Background - </i>The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic triple negative breast cancer (TNBC) wild type for BRCA1/2, we hypothesized that PARPi may be effective in primary TNBCs without previous chemotherapy exposure. < ...

    • Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel 

      Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjøsne, Hans Erikssønn; Nysted, Arne; Lillehaug, Johan R.; Lønning, Per Eystein (Journal article; Tidsskriftartikkel; Peer reviewed, 2011)
      TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wildtype p53 protein activity. Here, we explored the predictive and prognostic value of TP53 and CHEK2 mutation status together with MDM2 SNP309 genotype in stage III breast cancer ...